Loading [MathJax]/jax/output/SVG/jax.js
Review

Pharmacological and therapeutic inventory of fungi in cancertherapy—A comprehensive review

  • Cancer remains one of the foremost causes of death worldwide. Despite advancements in pharmaceutical therapies, patients continue to experience adverse effects. Consequently, there is a considerable interest in exploring mushrooms as a supplemental cancer treatment. In Asian countries, edible and medicinal mushrooms have long been consumed in both culinary practices and herbal remedies. Their health and nutritional benefits have also garnered rising attention in Europe. Food-grade mushrooms have a variety of pharmacological properties, including soothing and immunomodulating effects, and are associated with abundant therapeutic benefits. The primary mechanisms behind their anticancer activity comprise immune system improvement, cell cycle arrest, regulation of apoptosis, prevention of metastasis, and inhibition of cancer cell growth. Here, we thoroughly review the anticancer activities of several culinary and medicinal mushrooms, as well as some endophytic fungi, with a particular focus on potential bioactive compounds and their molecular mechanisms.

    Citation: Madhurima Roy, Chandana Paul, Nilasish Pal, Tanima Saha, Nirmalendu Das. Pharmacological and therapeutic inventory of fungi in cancertherapy—A comprehensive review[J]. AIMS Molecular Science, 2025, 12(1): 67-98. doi: 10.3934/molsci.2025005

    Related Papers:

    [1] Cheng-Cheng Zhu, Jiang Zhu . Spread trend of COVID-19 epidemic outbreak in China: using exponential attractor method in a spatial heterogeneous SEIQR model. Mathematical Biosciences and Engineering, 2020, 17(4): 3062-3087. doi: 10.3934/mbe.2020174
    [2] Yongli Cai, Yun Kang, Weiming Wang . Global stability of the steady states of an epidemic model incorporating intervention strategies. Mathematical Biosciences and Engineering, 2017, 14(5&6): 1071-1089. doi: 10.3934/mbe.2017056
    [3] Danfeng Pang, Yanni Xiao . The SIS model with diffusion of virus in the environment. Mathematical Biosciences and Engineering, 2019, 16(4): 2852-2874. doi: 10.3934/mbe.2019141
    [4] Pengfei Liu, Yantao Luo, Zhidong Teng . Role of media coverage in a SVEIR-I epidemic model with nonlinear incidence and spatial heterogeneous environment. Mathematical Biosciences and Engineering, 2023, 20(9): 15641-15671. doi: 10.3934/mbe.2023698
    [5] Azmy S. Ackleh, Keng Deng, Yixiang Wu . Competitive exclusion and coexistence in a two-strain pathogen model with diffusion. Mathematical Biosciences and Engineering, 2016, 13(1): 1-18. doi: 10.3934/mbe.2016.13.1
    [6] Youshan Tao, J. Ignacio Tello . Nonlinear stability of a heterogeneous state in a PDE-ODE model for acid-mediated tumor invasion. Mathematical Biosciences and Engineering, 2016, 13(1): 193-207. doi: 10.3934/mbe.2016.13.193
    [7] Wenzhang Huang, Maoan Han, Kaiyu Liu . Dynamics of an SIS reaction-diffusion epidemic model for disease transmission. Mathematical Biosciences and Engineering, 2010, 7(1): 51-66. doi: 10.3934/mbe.2010.7.51
    [8] Nalin Fonseka, Jerome Goddard Ⅱ, Alketa Henderson, Dustin Nichols, Ratnasingham Shivaji . Modeling effects of matrix heterogeneity on population persistence at the patch-level. Mathematical Biosciences and Engineering, 2022, 19(12): 13675-13709. doi: 10.3934/mbe.2022638
    [9] Liqiong Pu, Zhigui Lin . A diffusive SIS epidemic model in a heterogeneous and periodically evolvingenvironment. Mathematical Biosciences and Engineering, 2019, 16(4): 3094-3110. doi: 10.3934/mbe.2019153
    [10] Shuangshuang Yin, Jianhong Wu, Pengfei Song . Analysis of a heterogeneous SEIRS patch model with asymmetric mobility kernel. Mathematical Biosciences and Engineering, 2023, 20(7): 13434-13456. doi: 10.3934/mbe.2023599
  • Cancer remains one of the foremost causes of death worldwide. Despite advancements in pharmaceutical therapies, patients continue to experience adverse effects. Consequently, there is a considerable interest in exploring mushrooms as a supplemental cancer treatment. In Asian countries, edible and medicinal mushrooms have long been consumed in both culinary practices and herbal remedies. Their health and nutritional benefits have also garnered rising attention in Europe. Food-grade mushrooms have a variety of pharmacological properties, including soothing and immunomodulating effects, and are associated with abundant therapeutic benefits. The primary mechanisms behind their anticancer activity comprise immune system improvement, cell cycle arrest, regulation of apoptosis, prevention of metastasis, and inhibition of cancer cell growth. Here, we thoroughly review the anticancer activities of several culinary and medicinal mushrooms, as well as some endophytic fungi, with a particular focus on potential bioactive compounds and their molecular mechanisms.



    The idea of invisible living creatures as agents of disease goes back at least to the writings of Aristotle (384 BC–322 BC). In the 16th century, it developed as a theory. The AIDS epidemic, the recent SARS epidemic, MERS, Ebola virus and outbursts of diseases such as the Zika virus are events of concern and interest to many people. The mechanism of transmission of infections is now known for most diseases. Some diseases transmitted by viral agents, such as influenza, measles, rubella and chicken pox, confer immunity against reinfection, others transmitted by bacteria, such as tuberculosis, meningitis, and gonorrhea, confer no immunity against reinfection. While malaria, is transmitted not directly from human to human but by vectors, usually insects that are infected by humans transmit the disease to humans. There are also diseases such as West Nile virus which are transmitted back and forth between animals and vectors [1]. The first known result in mathematical epidemiology is a defense of the practice of inoculation against smallpox in 1760 by Daniel Bernouilli. The first contributions to modern mathematical epidemiology are due to P.D. En'ko between 1873 and 1894 [2], then many scholars pay more attention to the global stability problem [3,4,5,6,7], bifurcation problem [8,9,10,11] and the optimal control problem [12,13] of the disease.

    Recently, reaction–diffusion equations have been used by many authors in epidemiology as well as virology. Researchers have established many types of model with diffusion such as SIR model [14,15], SIS model [16], Lyme disease model [17,18], malaria model [19] and so on. Some authors specifically study the global stability of the spread of diseases [20,21,22,23,24,25,26,27]; others discuss the traveling wave solutions about reaction–diffusion models [28,29,30,31,32,33]. The authors of [34] applied energy estimates in their proofs to discussed cholera epidemic.

    In the theory of epidemiology, it has been recognized that environmental heterogeneity is a significant factor in the spread of infectious diseases. Constrained by factors such as altitude, temperature, humidity, latitude, climate, and living factors, the diffusion of epidemics in different environments is vastly different. In 2008, Allen et al. [35] proposed a simple diffusive SIS (susceptible–infected–susceptible) model with space-dependent disease transmission rate β(x) and recovery rate γ(x), given by

    {St=dSΔSβ(x)SIS+I+γ(x)I, xΩ,t>0,It=dIΔI+β(x)SIS+Iγ(x)I, xΩ,t>0,Sn=In=0, xΩ,t>0,S(x,0)=S0(x),I(x,0)=I0(x), xΩ. (1.1)

    where Ω is a bounded domain in Rm and S+I is the total number of individuals at t=0. They studied the existence, uniqueness, stability of the disease-free equilibrium and studied the asymptotic behavior of the unique endemic equilibrium as dS approaches zero. More precisely, their results implied that if the spatial environment can be modified to include low-risk sites and the movement of susceptible individuals can be restricted, then it may be possible to eliminate the infectious disease. In some subsequent work, Peng [36] discussed the asymptotic profiles of the steady states for the epidemic reaction–diffusion model (1.1). The global stability of the steady states of (1.1) was also investigated by Peng and Liu [37] in 2009. Four years later, Peng and Yi [38] studied the effects of epidemic risk and population movement on the spatiotemporal transmission of infectious disease via the SIS epidemic reaction–diffusion model (1.1). In 2011, Lou and Zhao [19] introduced a reaction–diffusion malaria model with incubation period in the vector population. Kuniya and Wang [39] gave the Lyapunov functions and global stability for a spatially diffusive SIR epidemic model for only one diffusion, for systems with multiple diffusions, the author did not get the method to construct the Lyapunov function. Deng and Wu [40] discussed the global dynamics of a SIS epidemic reaction-diffusion model, which reads as follows:

    {St=dSΔSβ(x)SI+γ(x)I, xΩ,t>0,It=dIΔI+β(x)SIγ(x)I, xΩ,t>0,Sn=In=0, xΩ,t>0,S(x,0)=S0(x),I(x,0)=I0(x), xΩ. (1.2)

    The authors only discussed the attractivity and global stability of the constant coefficient model, and constructed the Lyapunov function of the constant system. Wu and Zou [41] analyzed the asymptotic profiles of steady states for the model (1.2) with mass action infection mechanism. In 2017, Li et al. [42] studied the following SIS reaction-diffusion system with a linear external source:

    {StdSΔS=Λ(x)Sβ(x)SIS+I+θγ(x)I, xΩ,t>0,ItdIΔI=β(x)SIS+Iγ(x)I, xΩ,t>0,Sn=In=0, xΩ,t>0,S(x,0)=S0(x),I(x,0)=I0(x), xΩ. (1.3)

    The authors showed the uniform bounds of solutions, established the threshold dynamics in terms of the basic reproduction number and discussed the global stability of the unique constant endemic equilibrium when spatial environment is homogeneous. In particular, the asymptotic profile of endemic equilibria is determined if the diffusion rate of the susceptible or infected population at 0 or . Since the Lyapunov function is difficult to construct, the authors did not discuss the global stability of endemic for heterogeneous models. In 2018, Cai et al. [43] investigated the dynamical outcomes of a host–parasite model incorporating both horizontal and vertical transmissions in a spatial heterogeneous environment. The work of Tong and Lei [44] concerns an SIS epidemic reaction–diffusion model. They also failed to construct Lyapunov functions suitable for spatial heterogeneous models. Therefore, the construction of the Lyapunov function of the spatial heterogeneous model is very difficult. In discussing the long-term dynamic behavior of disease in space, we also need to try to find other methods.

    On the other hand, many diseases such as hepatitis, malaria, rabies, tuberculosis and HIV/AIDS will produce relapse after being treatment. We also know that vaccination is an important means of preventing infection and relapse of these diseases. Therefore, the effect of spatial factors on relapse and vaccination should be taken into account. Inspired by the above literature, in this manuscript, we study an SVIR epidemic reaction-diffusion model with relapse and a varying external source in spatially heterogeneous environment. This model has the following significant differences and difficulties compared to the above models. First, after joining the relapse, the coupling between the equations in the system is stronger. Thus, the method to prove the positivity of the solution in the prior literature can no longer be used in the coupled model. Second, because the coefficients in the model are all spatially heterogeneous and the number of equations increases, so the Lyapunov function method, which proves the global asymptotic stability of the system, is also difficult to achieve due to the increased technical difficulty of construction. For this reason, we turn to discuss the global dynamics of the system by using the attractor theory of infinite dimensional dynamical systems. It is well-known that the global attractor is an important theory to describe the long-term dynamic behavior of dissipative infinite-dimensional dynamical systems [45,46,47,48,49,50,51,52,53,54]. Finally, we conduct a large number of numerical simulations. From the simulation we can see that spatial heterogeneity has a great influence on the long-term dynamic behavior of epidemics. Reducing the relapse rate and increasing the vaccination rate can effectively control the spread of the disease.

    The organization of this paper is as follows. In Section 2, we present the model under some assumption. Then by using general comparison principle of the quasi-monotone nonlinear reaction-diffusion system and the comparison principle of parabolic equation, we prove the existence of the positive solutions. We also give the uniform boundedness and the existence of global solutions to our system. In Section 3, we prove the existence theorem of global exponential attract set for our real model and apply this result to discuss the global stability and the persistence of the infection disease. That is, by applying the property of global attractor and gradient flow method, we prove that the non-constant disease-free equilibrium is globally asymptotically stable and the endemic is persisting uniformly under some new threshold conditions. To test the validity of our theoretical results, we choose some specific epidemic disease with some more practical and more definitive official data to simulate the global stability and exponential attraction of the model. The stability and global exponential attractiveness of both constant and non-constant equilibria are simulated in Section 4. In Section 5, we give our conclusions and some discussions.

    In this section, we consider a reaction-diffusion SVIR model with relapse and spatially heterogeneous environment. Our model is divided into four compartments, namely the susceptible individuals (S), vaccinated individuals (V), infected individuals (I) and temporary restorers (R). The transfer diagram and parameters description as shown below:

    From Figure 1, the following system with the initial-boundary-value conditions is constructed by:

    {St=dSΔS+Λ(x)β1(x)SIS+I[μ(x)+α(x)]S, xΩ,t>0,Vt=dVΔV+α(x)Sβ2(x)VIV+Iμ(x)V, xΩ,t>0,It=dIΔI+β1(x)SIS+I+β2(x)VIV+I+ρ(x)R[μ(x)+η1(x)+ϕ(x)]I, xΩ,t>0,Rt=dRΔR+ϕ(x)I[ρ(x)+μ(x)+η2(x)]R, xΩ,t>0,Sn=Vn=In=Rn=0, xΩ,t>0,S(x,0)=S0(x),V(x,0)=V0(x),I(x,0)=I0(x),R(x,0)=R0(x), xΩ. (2.1)
    Figure 1.  Transfer diagram for the SVIR model with relapse and spatially heterogeneous environment.

    Here, Ω is a bounded domain in Rm(m1) with smooth boundary Ω (when m>1), dS,dV,dI,dR>0 are diffusion coefficients and α(x),β1(x),β2(x),ρ(x),ϕ(x),μ(x),η1(x),η2(x) and Λ(x) are positive Hölder continuous functions on accounting for the rates of vaccination, disease transmission, relapse, recovery, natural death, disease-related death and total recruitment scale respectively. Neumann boundary conditions Sn=Vn=In=Rn=0 denotes that the change rate on the boundary of the region Ω is equal to 0. It is straightforward to verify that SIS+I (VIV+I) is a Lipschitz continuous function of S (V) and I in the open first quadrant. Therefore, we can extend it to the entire first quadrant by defining it to be zero whenever S=0 (V=0) or I=0. Throughout the paper, we assume that the initial value S0(x),V0(x),I0(x) and R0(x) are nonnegative continuous functions on ¯Ω, and the number of infected individuals is positive, i.e., ΩI0(x)dx>0. Specific parameters described in Table 1.

    Table 1.  State variables and parameters of SVIR model.
    Parameter Description
    S(x,t) Density of susceptible individuals at location x and time t.
    V(x,t) Density of vaccinated individuals at location x and time t.
    I(x,t) Density of infected individuals at location x and time t.
    R(x,t) Density of temporary restorers at location x and time t.
    Λ(x) Total recruitment scale into this homogeneous social mixing community at location x.
    α(x) Vaccination rate at location x.
    βi(x),i=1,2 Effective transmission rate (average number of effective interactions per susceptible, vaccination individuals and infected individuals) at location x.
    ρ(x) Relapse rate at location x.
    ϕ(x) Per-capita recovery (treatment) rate at location x.
    μ(x) Natural mortality rate at location x.
    ηi(x),i=1,2 Disease-related death rate at location x.

     | Show Table
    DownLoad: CSV

    With the development of science and technology and the improvement of medical standards, vaccines play an important role in the prevention and control of disease transmission. So we considered a group of people who were vaccinated with preventive vaccines in the model (2.1). In the model, I denotes the infected person, and R denotes the person who is temporarily recovered by treatment after the infection but may also relapse. These two groups of people carry the disease-causing virus, so we need to consider their disease-induced rates. S denotes a susceptible population, and V denotes an uninfected person who has been vaccinated. They are not ill before they are exposed to pathogenic bacteria or infected people, so we only need to consider the natural mortality of these two types of people. There are many diseases in real life that have such properties, such as hepatitis B, smallpox, etc.,

    In the following, we discuss the positivity and boundedness of the solution of system (2.1). In many articles, the positivity, boundedness, and existence of solutions of the model have been discussed, such as models that lose immunity in [55,56,57]. The authors in [55] construct a model of ordinary differential equations, which is naturally less difficult for the proof of positive, boundedness, and existence of solutions. For example, the positive problem of the solution can be easily obtained through contradiction analysis even without using the comparison principle. The model in our manuscript is diffused, and the difficulty of analysis is naturally higher than that of the ODE model. Models in [56] and [57] are diffusion models, and the model of [57] assumes that all diffusion coefficients are equal at the time of construction. In [56], when discussing the existence of the solution of the model (Theorem 2.1 in [56]), the condition that the diffusion coefficients are equal is added. We all know that it is very easy to add the equations in the system when the diffusion coefficients are equal, and then researchers can discuss positivity, boundedness and existence of the solution for this equation about the rate of change of the total population. However, the model diffusion coefficients in our manuscripts are different, we refuse to add any conditions to the diffusion coefficient from beginning to end. Therefore, from the perspective of the diffusion system, our model is more general. These are places where our models and discussion methods differ from other existing results. Firstly, we give an comparison theorem for semilinear parabolic differential equation that we need to use later.

    Denote

    QT=Ω×(0,T],  ST=Ω×(0,T],Linj,k=1a(i)jk(x)2xjxk+nj=1b(i)j(x)xj,Biui=ui or Biui=uin+bi(x)ui,

    where n is the unit outside normal vector of Ω and bi(x)0. The following lemma is similar to the Theorem 4.2.9 in Chinese books [58], but for the convenience of the reader, we give its conclusions and a brief proof.

    Lemma 2.1. Let u,vC2,1(QT)C(¯QT), satisfy

    {Liuifi(x,t,u)Livifi(x,t,v),(x,t)QT,BiuiBivi,(x,t)ST,ui(x,0)vi(x,0),i=1,2,...,m,

    and

    fiuj0,ij,i,j=1,2,...,m.

    Then

    (1) u(x,t)v(x,t) in QT.

    (2) If there exist (x0,t0)QT and μ:0μm, such that (uv)μ(x0,t0)=0, then for any (x,t)¯Qt0, there has (uv)μ(x,t)=0.

    Proof. Let w=uv, then by using differential mean value theorem for multivariate functions

    LiuiLivi[fi(x,t,u)fi(x,t,v)]=Liwi[fi(x,t,u1,u2,u3,...,um1,um)fi(x,t,v1,u2,u3,...,um1,um)+fi(x,t,v1,u2,u3,...,um1,um)fi(x,t,v1,v2,u3,...,um1,um)+...+fi(x,t,v1,v2,v3,...,vm1,um)fi(x,t,v1,v2,v3,...,vm1,vm)]=Liwimj=1fiuj(x,t,v1,...,vj1,vj+ξj(ujvj),vj+1,...,um)(ujvj)=:Liwi+mj=1hijwj0, i=1,2,...,m.

    In view of fiuj0,ij,i,j=1,2,...,m, therefore, hij=fiuj0. If x¯Ω, we have w(x,0)0 and Biwi|ST0,i=1,2,...,m. Then by the strong maximum principle in the form of equation derivatives, we can prove that w(x,t)0, that is u(x,t)v(x,t) in QT. Finally, if there exist (x0,t0)QT and μ:0μm, such that wμ(x0,t0)=0, then for any (x,t)¯Qt0, there has wμ(x,t)=0, that is (uv)μ(x,t)=0.

    The above lemma can also be derived indirectly from [59,Theorem 7.3.4]. Let X:=L2(Ω) be a Banach space, L1,L2,L3 and L4 be a linear operator on D(L)=(D(L1),D(L2),D(L3),D(L4))X defined by

    L1S(x):=dSΔS(x),L2V(x):=dVΔV(x),L3I(x):=dIΔI(x),L4R(x):=dRΔR(x),D(L1):={SH2(Ω);Sn=0 on Ω},D(L2):={VH2(Ω);Vn=0 on Ω},D(L3):={IH2(Ω);In=0 on Ω},D(L4):={RH2(Ω);Rn=0 on Ω}.

    Then, we can see that L1,L2,L3,L4 are respectively the infinitesimal generator of strongly continuous semigroup {etL1}t0,{etL2}t0,{etL3}t0,{etL4}t0 in H2(Ω). Let (H2(Ω))4=H2(Ω)×H2(Ω)×H2(Ω)×H2(Ω) and define L:(H2(Ω))4(H2(Ω))4,u:=(S,V,I,R)(H2(Ω))4, then

    L(S,V,I,R)(x):=(L1S(x)L2V(x)L3I(x)L4R(x)), D(L):=D(L1)×D(L2)×D(L3)×D(L4)

    is also the infinitesimal generator of a strongly continuous semigroup {etL}t0 in Y:=(H2(Ω))4, where

    etL=(etL1etL2etL3etL4) and etLu=(etL1SetL2VetL3IetL4R).

    Note that Y is a Banach space equipped with norm

    (S,V,I,R)TY:=max{SH2(Ω),VH2(Ω),IH2(Ω),RH2(Ω)}.

    Let G be a nonlinear operator on Y defined by

    G(S,V,I,R)(x):=(g1(S,V,I,R)(x),g2(S,V,I,R)(x),g3(S,V,I,R)(x),g4(S,V,I,R)(x))T,

    where

    g1(S,V,I,R)(x)=Λ(x)β1(x)SIS+I[μ(x)+α(x)]S,g2(S,V,I,R)(x)=α(x)Sβ2(x)VIV+Iμ(x)V,g3(S,V,I,R)(x)=β1(x)SIS+I+β2(x)VIV+I+ρ(x)R[μ(x)+η1(x)+ϕ(x)]I,g4(S,V,I,R)(x)=ϕ(x)I[ρ(x)+μ(x)+η2(x)]R.

    Let F=(f1,f2,f3,f4), where

    fi(S,V,I,R)={gi(S,V,I,R)(x), S,V,I,R>0,0, others, i=1,2,3,4.

    Using the operators L and F defined by above, we can rewrite the problem (2.1) into the following abstract form in Y.

    ddtu(t)=Lu(t)+F(u(t)), u(t):=(S(,t)V(,t)I(,t)R(,t)), u(0):=(S0()V0()I0()R0.()). (2.2)

    Because L is the generator of a C0-semigroup of contractions on Y and F is locally Lipschitz with respect to u, apply [60,Corollary 11.1.2] and [60,Corollary 11.3.1], we know that there exists at least one saturated solution u:[0,T)Y, which is a classical solution of system (2.2), such that

    u(t)=etLu0+t0e(ts)LF(u(s))ds. (2.3)

    Moreover, if S(x,0),V(x,0),I(x,0),R(x,0)C2(Ω), then u(x,t)C2,1(Ω×(0,T]).

    In the following, we discuss the positivity of the solution of system (2.2) and the existence of the solution of system (2.1).

    Theorem 2.2. Assume that (S(x,t),V(x,t),I(x,t),R(x,t)) be a solution of system (2.2), and S(x,t),V(x,t),I(x,t),R(x,t)C(¯Ω×(0,T])C2,1(Ω×(0,T]) where T is the maximal existing time. If S(x,0)>0,V(x,0)>0,I(x,0)>0,R(x,0)>0 for xΩ, then the solution S(x,t)>0,V(x,t),>0,I(x,t)>0,R(x,t)>0,(x,t)Ω×(0,T] and u(t)=(S(x,t),V(x,t),I(x,t),R(x,t)) is a solution ofsystem (2.1).

    Proof. We denote that

    ~f1(S,V,I,R)={β1(x)SIS+I[μ(x)+α(x)]S, S,V,I,R>0,0, others, ~f2(S,V,I,R)={β2(x)VIV+Iμ(x)V, S,V,I,R>0,0, others.

    It is obviously that ~f1(S,V,I,R)f1(S,V,I,R) and 0 is a solution of equation

    {StdSΔS=~f1(S,V,I,R),Sn=0,S(x,0)=0.

    If S is the solution of the equation

    {StdSΔS=f1(S,V,I,R),Sn=0,S(x,0)=S0(x)>0.

    then by using [61,Theorem 2.2.1], we get S(x,t)>0. Similarly, it is obviously that ~f2(S,V,I,R)f2(S,V,I,R) and 0 is a solution of equation

    {VtdVΔV=~f2(S,V,I,R),Vn=0,V(x,0)=0.

    If V is the solution of the equation

    {VtdVΔV=f2(S,V,I,R),Vn=0,V(x,0)=V0(x)>0.

    then by using [61,Theorem 2.2.1], we get V(x,t)>0. At this time, S and V are just the solutions of the first and the second equations system (2.2). Then for the third and the forth equations of system (2.2), we know that

    f3R={ρ(x), S,V,I,R>0,0, others, f4I={ϕ(x), S,V,I,R>0,0, others, 

    therefore, f3R0,f4I0. By the comparison principle Lemma 2.1, we can obtain I(x,t)>0 and R(x,t)>0. Because under the condition of S,V,I,R>0, we have F=G, therefore, u(t) is also the solution of (2.1).

    From now on, for any given continuous function f on ¯Ω, we denote

    f=maxx¯Ωf(x) and f=minx¯Ωf(x).

    In the following, we need to give the Gronwall type differential inequality. Moreover, we do not make assumptions about the positivity of all the functions that appear in the lemma. This lemma will play an important role in the proof of the following lemmas and theorems.

    Lemma 2.3. u(t),c(t),h(t) are three real functions defined on [a,T), u(t) is absolutely continuous on [a,T), c(t) is integrable on [a,T). If the following inequality holds,

    ddtu(t)+c(t)u(t)h(t),a.e.t[a,T), (2.4)

    then

    u(t)etac(τ)dτu(a)+taetsc(τ)dτh(s)ds.

    Theorem 2.4. Assume that (S(x,t),V(x,t),I(x,t),R(x,t)) be a solution of system (2.1), and S(x,t),V(x,t),I(x,t),R(x,t)C(¯Ω×(0,T])C2,1(Ω×(0,T]) where T is the maximal existing time. If S(x,0)>0,V(x,0)>0,I(x,0)>0,R(x,0)>0 for xΩ, then the solution (S(x,t),V(x,t),I(x,t),R(x,t)) uniformly bounded on ¯Ω.

    Proof. We consider the following total population at time t. Define

    U(t)=Ω[S(x,t)+V(x,t)+I(x,t)+R(x,t)]dx.

    From system (2.1), it is easy to see that

    dU(t)dt=Ω[tS(x,t)+tV(x,t)+tI(x,t)+tR(x,t)]dx=Ω{dSΔS+dVΔV+dIΔI+dRΔR+Λ(x)μ(x)Sμ(x)V[μ(x)+η1(x)]I[μ(x)+η2(x)]R}dxdSΩΔSdx+dVΩΔVdx+dIΩΔIdx+dRΩΔRdx+Ω{Λμ[S+V+I+R]}dx=dSΩSnds+dVΩVnds+dIΩInds+dRΩRnds+Λ|Ω|μU(t)=Λ|Ω|μU(t).

    By Lemma 2.3, we can obtain that

    U(t)U(0)eμt+Λ|Ω|μ(1eμt).

    So U(t)max{U(0),Λ|Ω|μ}, where

    U(0)=Ω[S(x,0)+V(x,0)+I(x,0)+R(x,0)]dxΩS(x,0)+V(x,0)+I(x,0)+R(x,0)dx=S(x,0)+V(x,0)+I(x,0)+R(x,0)|Ω|.

    This shows that U(t)=Ω(S+V+I+R)dx is bounded. By Theorem 2.2, we obtain that

    S+V+I+RL1(Ω)=Ω|S+V+I+R|(x,t)dx=Ω(S+V+I+R)(x,t)dxmax{S(x,0)+V(x,0)+I(x,0)+R(x,0)|Ω|,Λ|Ω|μ}.

    We denote that K=max{S(x,0)+V(x,0)+I(x,0)+R(x,0)|Ω|,Λ|Ω|μ}, then we know

    Ω(S+V+I+R)dxK.

    In view of [62,Lemma 2.1], there exists a positive constant K depending on K such that

    S+V+I+RL(Ω)K.

    Thus, we can obtain that S(x,t),V(x,t),I(x,t),R(x,t) are uniformly bounded on ¯Ω. This implies the boundedness of the solution of system (2.1).

    By [60,Corollary 11.3.2] we can deduce that the saturated solution u(t)=(S(x,t),V(x,t),I(x,t),R(x,t)) is either global or limt+u(t)Y=+. From Theorem 2.4 we know that u(t) is bounded, hence, u(t) is a global solution.

    In this section, we will analyze the qualitative behavior of system (2.1). It is clearly seen that system (2.1) admits a disease-free equilibrium E0(x)=(S0(x),V0(x),0,0), then we prove that the existence of principal eigenvalues of system (2.1). Linearizing the second and the third equations of (2.1) at disease-free equilibrium, we get

    {It=dIΔI+[β1(x)+β2(x)]I+ρ(x)R[μ(x)+η1(x)+ϕ(x)]I, xΩ,t>0,Rt=dRΔR+ϕ(x)I[ρ(x)+μ(x)+η2(x)]R, xΩ,t>0,In=Rn=0, xΩ,t>0. (3.1)

    Let I=eλtφ(x),R=eλtψ(x), equations (3.1) can be rewritten as

    {dIΔφ(x)+[β1(x)+β2(x)(μ(x)+η1(x)+ϕ(x))]φ(x)+ρ(x)ψ(x)=λφ(x), xΩ,dRΔψ(x)+ϕ(x)φ(x)[ρ(x)+μ(x)+η2(x)]ψ(x)=λψ(x), xΩ,φn=ψn=0, xΩ. (3.2)

    Denote Φ(x)=(φ(x),ψ(x))T,D=[dI00dR] and

    M(x)=(mij(x))=[β1(x)+β2(x)(μ(x)+η1(x)+ϕ(x))ρ(x)ϕ(x)[ρ(x)+μ(x)+η2(x)]],

    where mij(x)0,ij,x¯Ω. Therefore, equations (3.2) can be rewritten as

    {λΦ(x)=DΔΦ(x)+M(x)Φ(x), xΩ,Φn=0, xΩ (3.3)

    By [59,Theorem 7.6.1], we can obtain that there exists a real eigenvalue λ of Eq (3.3) and a corresponding eigenvector Φ(x) satisfying Φ(x)>>0 for all x¯Ω in the case of Neumann boundary conditions.

    Before discussing the global dynamics of the reaction-diffusion SVIR model with relapse and spatial heterogeneous in detail, we need to recall some concept and existing results of exponential attractor and measure of noncompactness.

    Let X be a Banach space with the decomposition

    X=X1X2; dimX1<

    and denote orthogonal projector by P:XX1 and (IP):XX2. In addition, let {Q(t)}t0 be a continuous semigroup on X. The following Condition (C*) introduced in [53] is an important condition for verifying the global exponential attraction.

    Condition (C*): For any bounded set BX there exist positive constants tB,C and α such that for any ε>0 there exists a finite dimensional subspace X1X satisfies

    {PQ(t)B}ttB is bounded, 
    (IP)Q(t)B<Ceαt+ε for ttB,

    where P:XX1 is a orthogonal projector.

    In the following, we denote that H=L2(Ω)C2,1(Ω), H1=H10(Ω)C2,1(Ω),H4=H×H×H×H and H41=H1×H1×H1×H1. Note that H4 and H41 are Banach spaces equipped with norm

    (S,V,I,R)TH4:=max{SH,VH,IH,RH}.

    and

    (S,V,I,R)TH41:=max{SH1,VH1,IH1,RH1}.

    Definition 3.1. ([49,Definition A.2.1]) A mapping L+G:H1H is called a gradient-type operator if there exists a C1 functional F:H1R1 and for some constant C>0 such that DF(u)H for every uHβ for some β1, and

    DF(u),Lu+G(u)HC1DF(u)2H, uH1,
    DF(u0)=0Lu0+G(u0)=0.

    In this case, F is called the energy functional of L+G.

    Theorem 3.2. System (2.1) exists a global exponential attract set A, it exponential attracts any bounded set in H4.

    Proof. It is known by the existence of the global solution that if φ=u(0)=(S0(x),V0(x),I0(x),R0(x))TH41, then system (2.1) has a global solution u=(S,V,I,R)TC0([0,),H4). It means that system (2.1) generates a operator semigroup Q(t)=(Q1(t),Q2(t),Q3(t),Q4(t))T and Q(t)φ=u(t,φ).

    We first prove that the operator semigroup Q(t) has an absorbing set BˆRH4. It follows from the inner product of the first equation of system (2.1) in H with S, we have that

    dSΔS+Λ(x)β1(x)SIS+I[μ(x)+α(x)]S,SH=dSΩSΔSdx+ΩΛ(x)SdxΩβ1(x)S2IS+IdxΩ[μ(x)+α(x)]S2dxdSS2H12+ΩΛ(x)SdxdSS2H12+ΛΩSdx,

    where H12 is the fractional power subspace generated by the sectorial operator L. From Theorem 2.2 and Theorem 2.4, we can obtain that S is positive and bounded. Hence, there exists a C1>0 such that

    ΛΩSdxC1.

    Since H12H, so there exists a C>0, such that

    SH12CSH, SH12.

    As we know that

    12ddtS,SH=St,SH,

    hence,

    12ddtS2HdSC2S2H+C1,

    By Lemma 2.3, we obtain that

    S2Heγ1tS0(x)2H+2C1γ1(1eγ1t),

    where γ1=2dSC2. It follows from the inner product of the second equation of system (2.1) in H with V, we have that

    dVΔV+α(x)Sβ2(x)VIV+Iμ(x)V,VH=dVΩVΔVdx+Ωα(x)SVdxΩβ2(x)V2IV+IdxΩμ(x)V2dxdVV2H12+αΩSVdx,

    From Theorem 2.2 and Theorem 2.4, we can obtain that S,V are positive and bounded. Hence, there exists a C2>0 such that

    αΩSVdxC2.

    Since H12H, so there exists a C>0, such that

    VH12CVH, VH12.

    Hence,

    12ddtV2HdVC2V2H+C2,

    By Lemma 2.3, we obtain that

    V2Heγ2tV0(x)2H+2C2γ2(1eγ2t),

    where γ2=2dVC2. It follows from the inner product of the third equation of system (2.1) in H with I, we have that

    dIΔI+β1(x)SIS+I+β2(x)VIV+I+ρ(x)R[μ(x)+η1(x)+ϕ(x)]I,IH=dIΩIΔIdx+Ωβ1(x)SI2S+Idx+Ωβ2(x)VI2V+Idx+Ωρ(x)IRdxΩ[μ(x)+η1(x)+ϕ(x)]I2dxdII2H12+Ωβ1(x)SI2S+Idx+Ωβ2(x)VI2V+Idx+Ωρ(x)IRdxdII2H12+(β1+β2)ΩI2dx+ρΩIRdx,

    From Theorem 2.2 and Theorem 2.4, we can obtain that I,R are positive and bounded. Hence, there exists a C3>0 such that

    (β1+β2)ΩI2dx+ρΩIRdxC35.

    Since H12H, so there exists a C>0, such that

    IH12CIH, IH12.

    Hence,

    12ddtI2HdIC2I2H+C3,

    By Lemma 2.3, we obtain that

    I2Heγ3tI0(x)2H+2C3γ3(1eγ3t),

    where γ3=2dIC2. It follows from the inner product of the forth equation of system (2.1) in H with R, we have that

    dRΔR+ϕ(x)I[ρ(x)+μ(x)+η2(x)]R,RH=dRΩRΔRdx+Ωϕ(x)IRdxΩ[ρ(x)+μ(x)+η2(x)]R2dxdRR2H12+ϕΩIRdx.

    From Theorem 2.2 and Theorem 2.4, we can obtain that there exists a C4>0 such that

    ϕΩIRdxC4.

    Since H12H, so there exists a C>0, such that

    RH12CRH, RH12.

    Hence,

    12ddtR2HdRC2R2H+C4,

    By Lemma 2.3, we obtain that

    R2Heγ4tR0(x)2H+2C4γ4(1eγ4t),

    where γ4=2dRC2. Therefore, it implies if ˆR2>max{2C1γ1,2C2γ2,2C3γ3,2C4γ4}, then there exists a t0>0, such that for any tt0, there has u(t,φ)BˆR. Thence, BˆRH4 is the absorbing set.

    Next we verify Condition (C*). Since L1=dSΔ:H1H is a symmetrical sectorial operator, so the eigenvectors {ej}jN corresponding to the eigenvalues {λS,j}jN are the complete orthonormal basis of H, that is for any SH,

    S=k=1xkek,S2H=k=1x2k.

    In addition, NS>0,KS1 such that NSλS,j,jKS+1.

    Let

    HKS1=span{e1,e2,...,eKS} and HKS2=(HKS1).

    Then, each SH can be decomposed as

    S=PS+(IP)S:=S1+S2,S1=KSi=1xieiHKS1, S2=j=KS+1xjejHKS2,

    where P:HHKS1 is the orthogonal projector. There are similar decomposition forms for each V,I,RH.

    Since Q(t) has a bounded absorbing set BˆRH4, then for any bounded set BH4, there exists a tB>0, without loss of generality, we assume that tB>t0 such that (S(t,S0(x)),V(t,V0(x)),I(t,I0(x)),R(t,R0(x)))BˆR, where

    S(t,S0(x))=Q1(t)S0(x),V(t,V0(x))=Q2(t)V0(x),I(t,I0(x))=Q3(t)I0(x),R(t,R0(x))=Q4(t)R0(x),

    (S0(x),V0(x),I0(x),R0(x))B,ttB, then

    S(t,S0(x))2H=Q1(t)S0(x)2HˆR2,ttB,V(t,V0(x))2H=Q2(t)V0(x)2HˆR2,ttB,I(t,I0(x))2H=Q3(t)I0(x)2HˆR2,ttB,R(t,R0(x))2H=QR(t)R0(x)2HˆR2,ttB.

    Hence,

    PQ(t)φH4ˆR, ttB.

    It means that {PQ(t)BH4}ttB is bounded.

    It follows from the inner product of the first equation of system (2.1) in H with S2, we have that

    12ddtS,S2H=St,S2H=dSΔS+Λ(x)β1(x)SIS+I[μ(x)+α(x)]S,S2H=dSΔS,S2H+Λ(x)β1(x)SIS+I[μ(x)+α(x)]S,S2H=dSΔS1+dSΔS2,S2H+Λ(x)β1(x)SIS+I[μ(x)+α(x)]S,S2HdSΔS2,S2H+Λ(x)β1(x)SIS+I[μ(x)+α(x)]S,S2H,

    where

    dSΔS2,S2H=dSS22H12=dSj=KS+1λS,jx2jdSNSj=KS+1x2j=dSNSS22H.

    Since ttB, SHˆR. Then

    Λ(x)β1(x)SIS+I[μ(x)+α(x)]S,S2HΛ(x)β1(x)SIS+I[μ(x)+α(x)]SHS2H(Λ(x)H+β1(x)SH+[μ(x)+α(x)]SH)ˆR[Λ+(β1+μ+α)ˆR]ˆR:=CS,ˆR.

    Hence,

    ddtS22H2dSNSu22H+2CS,ˆR.

    By Lemma 2.3,

    S22He2dSNS(ttB)S2(tB)2H+CS,ˆRdSNS(1e2dSNS(ttB)), ttB

    and NS>0 is arbitrary. Similarly,

    V22He2dVNV(ttB)V2(tB)2H+CV,ˆRdVNV(1e2dVNV(ttB)), ttB,
    I22He2dINI(ttB)I2(tB)2H+CI,ˆRdINI(1e2dINI(ttB)), ttB,
    R22He2dRNR(ttB)R2(tB)2H+CR,ˆRdRNR(1e2dRNR(ttB)), ttB

    and NV,NI,NR>0 are arbitrary. Therefore, we deduce that the Condition (C*) holds. By [53,Theorem 4.1], we obtain that system (2.1) has a global exponential attract set A.

    After getting the global exponential attract set, we discuss the stability and uniform persistence of the epidemic disease.

    Theorem 3.3. The following statements are valid.

    (1) If λ<0, then

    limtS(x,t)=S0(x),limtV(x,t)=V0(x),limtI(x,t)=0,limtR(x,t)=0

    in H, and hence, the disease-free equilibrium is globally asymptotically stable.

    (2) If λ>0, then there exists a function γ(x)>0 independent of the initial data, such that any solution (S,V,I,R) satisfies

    liminftS(x,t)γ(x),liminftV(x,t)γ(x),liminftI(x,t)γ(x),liminftR(x,t)γ(x)

    for x¯Ω, and hence, the disease persists uniformly.

    Proof. (1) Suppose λ<0. Using the comparison principle, we can show that I(x,t)0,R(x,t)0 as t for every xΩ. First, we observe from the system (2.1) that

    {ItdIΔI+{β1(x)+β2(x)[μ(x)+η1(x)+ϕ(x)]}I+ρ(x)R,      xΩ,t>0,RtdRΔR+ϕ(x)I[ρ(x)+μ(x)+η2(x)]R, xΩ,t>0.

    Next, let us define (˜I(x,t),˜R(x,t))=(Meλtφ(x),Meλtψ(x)) where λ<0,φ(x)>>0,ψ(x)>>0 are the eigenvalue and eigenvectors in equations (3.2) and M is chosen so large that I(x,0)˜I(x,0),R(x,0)˜R(x,0) for every xΩ. It can be easily shown that (˜I(x,t),˜R(x,t)) satisfies

    {˜It=dIΔ˜I+{β1(x)+β2(x)[μ(x)+η1(x)+ϕ(x)]}˜I+ρ(x)˜R,     xΩ,t>0,˜Rt=dRΔ˜R+ϕ(x)˜I[ρ(x)+μ(x)+η2(x)]˜R, xΩ,t>0,˜In=˜Rn=0, xΩ.

    By the comparison principle Lemma 2.1, I(x,t)˜I(x,t),R(x,t)˜R(x,t) for every xΩ and t0. Since ˜I(x,t)0,˜R(x,t)0 as t for every xΩ, we also have that I(x,t)0,R(x,t)0 as t for every xΩ.

    Next we claim S(,t)S0(x) uniformly on as t. Given any small constant ε>0, there exists a large time T>0 such that 0I(x,t)ε for all x¯Ω,tT. From the first equation in system (2.1), it is easily observed that S is a super-solution to

    {wtdSΔw=Λ(x)β1ε[μ(x)+α(x)]w, xΩ,tT,wn=0, xΩ,w(x,T)=S(x,T), xΩ (3.4)

    and a sub-solution to

    {vtdSΔv=Λ(x)[μ(x)+α(x)]v, xΩ,tT,vn=0, xΩ,v(x,T)=S(x,T), xΩ. (3.5)

    Denote by w and v the solution of system (3.4) and system (3.5), respectively. The parabolic comparison principle gives

    w(x,t)S(x,t)v(x,t) for all x¯Ω,tT.

    For system (3.4), we can verify that

    dSΔw+Λ(x)β1ε[μ(x)+α(x)]w,wH=dSΩwΔwdx+ΩΛ(x)wdxΩβ1εwdxΩ[μ(x)+α(x)]w2dxdSw2H12+ΛΩwdx.

    It is similar to the proof of Theorem 3.2, we can obtain that system (3.4) exists a global exponential attract set Aw. In addition, system (3.4) has a variational structure, the corresponding functional of the variational structure is

    F(w)=Ω[dS2|w|2g(x,w)]dx,

    where

    g(x,w)=w0[Λ(x)β1ε[μ(x)+α(x)]w]dw.

    Then

    DF(w),Lw+G(w)H=DF(w),dSΔw+Λ(x)β1ε[μ(x)+α(x)]wHCDF(w)2H,

    where C>0, so L+G is a gradient type operator. From [49,Theorem A.2.2], we can prove that

    limtw(x,t)=S0(ε,x) in H

    where S0(ε,x) is the unique positive steady state of problems (3.4). Similarly, for system (3.5), we can obtain

    limtv(x,t)=S0(x) in H

    where S0(x) is the unique positive steady state of problems (3.5). Furthermore, due to the arbitrariness of ε, it is checked that

    S0(ε,x)S0(x) in H, as ε0.

    Thus, our analysis implies that S(,t)S0(x) uniformly on as t. Similarly, we can also prove that V(,t)V0(x) uniformly on as t.

    (2) Since λ>0. It is observed that the solution of

    {StdSΔS=Λ(x)[β1(x)+μ(x)+α(x)]S, xΩ,tT,Sn=0, xΩ,S(x,T)=S(x,T), xΩ (3.6)

    is a sub-solution of the first equation in (2.1). Similar to the proof of conclusion (1), system (3.6) is also a gradient type equation. From [49,Theorem A.2.2], we can prove that

    limtS(x,t)=S(x) in H

    By weak maximum principle, we know that S(x)>0 for all xΩ. Similarly, we can also prove that V(x)>0 for all xΩ. Next, let us define (I(x,t),R(x,t))=(εφ(x),εψ(x)) where φ(x)>>0,ψ(x)>>0 are the eigenvalue and eigenvectors in equations (3.2) and ε>0 is a sufficiently small constant. Substituting εφ,εψ into the third and the forth equations of system (2.1), we know

    εdIΔφ+β1(x)SεφS+εφ+β2(x)VεφV+εφ+ερ(x)ψε[μ(x)+η1(x)+ϕ(x)]φ(εφ)t=εdIΔφ+β1(x)SεφS+εφ+β2(x)VεφV+εφ+ερ(x)ψε[μ(x)+η1(x)+ϕ(x)]φ+εβ1(x)φεβ1(x)φ+εβ2(x)φεβ2(x)φ=ε{dIΔφ+[β1(x)+β2(x)]φ[μ(x)+η1(x)+ϕ(x)]φ+ρ(x)ψ}+εβ1(x)φ[SS+εφ1]+εβ2(x)φ[VV+εφ1]=εφ[λ+β1(x)(SS+εφ1)+β2(x)(VV+εφ1)]>0

    and

    εdRΔψ+εϕ(x)φε[ρ(x)+μ(x)+η2(x)]ψ(εψ)t=ε[dRΔψ+ϕ(x)φ[ρ(x)+μ(x)+η2(x)]ψ]=ελψ>0.

    Therefore, (εφ,εψ) is the sub-solution of the third and the forth equations of system (2.1). We choose 0<γ(x)<min{S(x),V(x),εφ(x),εψ(x)}, we can obtain that

    liminftS(x,t)γ(x),liminftV(x,t)γ(x),liminftI(x,t)γ(x),liminftR(x,t)γ(x)

    for x¯Ω, then it shows that the disease persists.

    The synthesis of Theorem 3.2 and Theorem 3.3 can give the following results: if λ>0, then the positive solution of system (2.1) is globally exponential attractive and the attraction domain is A. From an epidemiological point of view, the disease persists in this situation. The epidemic is globally asymptotically stable or attracted by the global exponential attract set.

    In this section, we hope to select a specific epidemic disease with some more practical and more definitive data to simulate the stability of our SVIR model with relapse. As we know, HBV epidemic model is a kind of infectious disease model with relapse and vaccination is the most effective way to prevent hepatitis. WHO also releases global hepatitis report every year. From "Global Hepatitis Report, 2017" [63], we know that in worldwide, approximately 240 million people have chronic hepatitis B virus infection. Without an expanded and accelerated response, the number of people living with hepatitis B virus is projected to remain at the current, high levels for the next 40-50 years, with a cumulative 20 million deaths occurring between 2015 and 2030. A stepped-up global response can no longer be delayed. From World Health Statistics [64], we can find that the data of global natural mortality, the male natural mortality rate is 19% and female natural mortality rate is 12.9% respectively. After a simple calculation we can get the natural mortality rate of the global is 15.95%. In conclusion, we can get the data in Table 2.

    Table 2.  The parameters description of HBV model.
    Parameter Description Data estimated Data sources
    Λ Recruitment scale of the population. 300year1 [63]
    β1 Estimated HBV prevalence (Transmission rate) without vaccination. 0.062year1 [63]
    β2 Estimated HBV prevalence (Transmission rate) with vaccination. 0.035year1 [63]
    α vaccinate rate. 0.39year1 [63]
    ρ Relapse rate. 0.3year1 Estimate
    ϕ The per-capita recovery (treatment) rate. 0.08year1 Estimate
    μ Natural mortality rate. 0.1595year1 [64]
    η1 The disease-related death rate of the HBV. 0.2year1 [63]
    η2 The disease-related death rate of being treated. 0.1year1 Estimate
    dS The diffusion coefficient of susceptible individuals. 2year1 Estimate
    dV The diffusion coefficient of vaccinated individuals. 2.5year1 Estimate
    dI The diffusion coefficient of infected individuals. 1.5year1 Estimate
    dR The diffusion coefficient of restored individuals. 5year1 Estimate

     | Show Table
    DownLoad: CSV

    According to the data in Table 2, we will first simulate the stability of the constant coefficient model about system (2.1) when Λ,β1,β2,α,ρ,ϕ,μ,η1 and η2 are assumed to be positive constants. Then we can obtain the stability of disease-free equilibrium of constant coefficient model (Figure 2).

    Figure 2.  The global stability of disease-free equilibrium of constant coefficient model.

    From the numerical simulation, it can be seen that although hepatitis B is still the primary disease endangering human health, however, the global hepatitis B disease has shown a trend of extinction.

    In this article, we discuss the dynamics of the epidemic model with a spatial heterogeneous environment, so we then simulate the stability and persistence of the spatial system (2.1). From the system (2.1) we can see that all the parameters are xrelated functions, so we choose different functions will directly lead to different stability results. We choose β1(x)=11+x,μ(x)=e2x,ϕ(x)=ex,ρ(x)=0.4sinx,η1(x)=0.2,η2(x)=0.1 and select other parameters from Table 2. We can show the global stability of non-constant disease-free equilibrium E0(x) of system (2.1) (Figure 3).

    Figure 3.  The global stability of non-constant disease-free equilibrium E0(x) of system (2.1) when β1(x)=11+x,μ(x)=e2x,ϕ(x)=ex,ρ(x)=0.4sinx,η1(x)=0.2,η2(x)=0.1.

    We choose μ(x)=ex,ϕ(x)=11+x,β1(x)=0.62,β2(x)=0.33ex and select other parameters from Table 2. We can obtain that the spatial heterogeneity epidemic is global stability (Figure 4).

    Figure 4.  The global stability of endemic of spatial heterogeneity system (2.1) when μ(x)=ex,ϕ(x)=11+x,β1(x)=0.62,β2(x)=0.33ex.

    We choose μ(x)=ex,ϕ(x)=11+x,ρ(x)=0.4sinx,β1(x)=0.62,β2(x)=0.33ex and select other parameters from Table 2. We can clearly see that the spatial heterogeneity epidemic is persists uniformly (Figure 5).

    Figure 5.  The spatial heterogeneity epidemic is persists uniformly when μ(x)=ex,ϕ(x)=11+x,ρ(x)=0.4sinx,β1(x)=0.62,β2(x)=0.33ex.

    In Figure 5, we can find that the image of the solution is turbulent, and the amplitude decreases with time. Finally, the image of the turmoil is controlled in range. And this range is the scope of the global exponential attract set. From the comparison of Figure 4 and Figure 5, we can find that spatial heterogeneity has a great impact on the spread of disease, and different parameters lead to changes in long-term dynamic behavior.

    From all above simulation we can clearly see that the disease-free equilibrium of the constant-coefficient model is global asymptotic stability. For spatial heterogeneous models, the stability of the model is dependent on the spatial parameters and diffusion coefficients. In addition, we can also see that the image whether rising or falling is very fast in the initial stage, which also confirms that the solutions of system (2.1) are global exponential attract.

    We have formulated a reaction-diffusion SVIR model with relapse in the spatially heterogeneous environment. We first prove the positivity of solution by using the comparison principle of monotone nonlinear reaction-diffusion dynamical system and comparison principle of parabolic equation. Most of the models in the previous work are non-coupled models or systems that contain only one diffusion equation. The usual way to study these two problems is to study one of the equations in the model first (such as eigenvalue problems or the existence of solutions), and then to get the properties of several other equations. However, the above methods do not applicable to the coupling system of the four diffusion equations we have established in this paper. In addition, we prove that the disease-free equilibrium is globally asymptotically stable and the endemic is persisting uniformly by the global exponential attract set theory. From our proof, we can find that λ has threshold characteristics. From the numerical simulation we can find the effect of spatial heterogeneity on the diffusion of disease is very large. Simulation results show that the best way to eliminate the disease is to control the contact rate. Reduce the relapse rate or increase the vaccination rate can make the disease tends to a stable state. Choosing different spatial coefficients can produce a fundamental change of the global dynamics of the system.

    The authors would like to thank the anonymous referees for their useful and valuable suggestions. The first author was supported by the Fundamental Research Funds for the Central Universities (JUSRP11949), NSF of China (11671180, 11671181) and the third author was supported by the science and technology foundation of Suqian(Z201444), China.

    The authors declare there is no conflict of interest.



    Conflict of interest



    The authors declare that they have no conflict of interest.

    [1] Giavasis I (2014) Bioactive fungal polysaccharides as potential functional ingredients in food and nutraceuticals. Curr Opin Biotechnol 26: 162-173. https://doi.org/10.1016/j.copbio.2014.01.010
    [2] Boels D, Landreau A, Bruneau C, et al. (2014) Shiitake dermatitis recorded by French Poison Control Centers—new case series with clinical observations. Clin Toxicol 52: 625-628. https://doi.org/10.3109/15563650.2014.923905
    [3] Kamalebo HM, Nshimba Seya Wa Malale H, Ndabaga CM, et al. (2018) Uses and importance of wild fungi: Traditional knowledge from the Tshopo province in the Democratic Republic of the Congo. J EthnobiolEthnomed 14: 13. https://doi.org/10.1186/s13002-017-0203-6
    [4] Sánchez C (2017) Reactive oxygen species and antioxidant properties from mushrooms. Syn SystBiotechno 2: 13-22. https://doi.org/10.1016/j.synbio.2016.12.001
    [5] Souilem F, Fernandes Â, Calhelha RC, et al. (2017) Wild mushrooms and their mycelia as sources of bioactive compounds: Antioxidant, anti-inflammatory and cytotoxic properties. Food Chem 230: 40-48. https://doi.org/10.1016/j.foodchem.2017.03.026
    [6] Wasser SP, Sokolov D, Reshetnikov SV, et al. (2000) Dietary supplements from medicinal mushrooms: Diversity of types and variety of regulations. Int JMed Mushrooms 2: 19. https://doi.org/10.1615/IntJMedMushr.v2.i1.10
    [7] Agnihotri C, Aarzoo, Agnihotri S, et al. (2024) Mushroom bioactives: Traditional resources with nutraceutical importance. Traditional resources and tools for modern drug discovery. Singapore: Springer 617-639. https://doi.org/10.1007/978-981-97-4600-2_24
    [8] Araújo-Rodrigues AH, Sofia Sousa BA, Pintado CME (2022) Chapter 6: Macromolecules in fungi with pharmaceutical potential. Edible fungi: Chemical composition, nutrition and health effects.Royal society of chemistry 232-272. https://doi.org/10.1039/9781839167522-00232
    [9] Bell V, Silva CRPG, Guina J, et al. (2022) Mushrooms as future generation healthy foods. Front Nutr 9: 1050099. https://doi.org/10.3389/fnut.2022.1050099
    [10] Sousa AS, Araújo-Rodrigues H, Pintado ME (2023) The health-promoting potential of edible mushroom proteins. Curr Pharm Des 29: 804-823. https://doi.org/10.2174/1381612829666221223103756
    [11] Chang ST, Wasser SP (2012) The role of culinary-medicinal mushrooms on human welfare with a pyramid model for human health. Int J Med Mushrooms 14: 95-134. https://doi.org/10.1615/IntJMedMushr.v14.i2.10
    [12] Dan A, Swain R, Belonce S, et al. (2023) Therapeutic effects of medicinal mushrooms on gastric, breast, and colorectal cancer: A scoping review. Cureus 15: e37574. https://doi.org/10.7759/cureus.37574
    [13] Bizuayehu HM, Ahmed KY, Kibret GD, et al. (2024) Global disparities of cancer and its projected burden in 2050. JAMA Netw Open 7: e2443198. https://doi.org/10.1001/jamanetworkopen.2024.43198
    [14] Dizon DS, Kamal AH (2024) Cancer statistics 2024: All hands on deck. CA: A Cancer Journal for Clinicians 74: 8-9. https://doi.org/10.3322/caac.21824
    [15] De Luca MG, Roda F, Rossi P, et al. (2024) Medicinal mushrooms in metastatic breast cancer: What is their therapeutic potential as adjuvants in clinical settings?. Curr Issues Mol Biol 46: 7577-7591. https://doi.org/10.3390/cimb46070450
    [16] De Luca F, Roda E, Ratto D, et al. (2023) Fighting secondary triple-negative breast cancer in the cerebellum: A powerful aid from a medicinal mushroom blend. Biomed Pharmacother 159: 114262. https://doi.org/10.1016/j.biopha.2023.114262
    [17] Bray F, Ren JS, Masuyer E, et al. (2013) Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 132: 1133-1145. https://doi.org/10.1002/ijc.27711
    [18] Alavi M, Farkhondeh T, Aschner M, et al. (2021) Resveratrol mediates its anti-cancer effects by Nrf2 signaling pathway activation. Cancer Cell Int 21: 579. https://doi.org/10.1186/s12935-021-02280-5
    [19] Hendrix A, Yeo AE, Lejeune S, et al. (2020) Rare case of life-threatening thrombocytopenia occurring after radiotherapy in a patient treated with an immune checkpoint inhibitor. BMJ Case Reports 13: e235249. https://doi.org/10.1136/bcr-2020-235249
    [20] Abravan A, Faivre-Finn C, Kennedy J, et al. (2020) Radiotherapy-related lymphopenia affects overall survival in patients with lung cancer. J Thorac Oncol 15: 1624-1635. https://doi.org/10.1016/j.jtho.2020.06.008
    [21] Arnon J, Meirow D, Lewis-Roness H, et al. (2001) Genetic and teratogenic effects of cancer treatments on gametes and embryos. Hum Reprod Update 7: 394-403. https://doi.org/10.1093/humupd/7.4.394
    [22] Rosangkima G, Prasad SB (2004) Antitumor activity of some plants from Meghalaya and Mizoram against murine ascites Dalton's lymphoma. Indian J Exp Biol 42: 981-988.
    [23] Sporn MB, Liby KT (2005) Cancer chemoprevention: Scientific promise, clinical uncertainty. Nat ClinPract Oncol 2: 518-525. https://doi.org/10.1038/ncponc0319
    [24] Araújo-Rodrigues H, Sousa AS, Relvas JB, et al. (2024) An overview on mushroom polysaccharides: Health-promoting properties, prebiotic and gut microbiota modulation effects, and structure-function correlation. CarbohydPolyme 333: 121978. https://doi.org/10.1016/j.carbpol.2024.121978
    [25] Buswell JA, Chang S (2024) Mushrooms: Fungi for all seasons. Acta Edulis Fungi 31: 11-30.
    [26] Berretta M, Dal Lago L, Tinazzi M, et al. (2022) Evaluation of concomitant use of anticancer drugs and herbal products: From interactions to synergic activity. Cancers 14: 5203. https://doi.org/10.3390/cancers14215203
    [27] Chan WJJ, Adiwidjaja J, McLachlan AJ, et al. (2023) Interactions between natural products and cancer treatments: Underlying mechanisms and clinical importance. Cancer ChemotherPharmacol 91: 103-119. https://doi.org/10.1007/s00280-023-04504-z
    [28] Habtemariam S (2019) The chemistry, pharmacology, and therapeutic potential of the edible mushroom Dictyophoraindusiata (Vent ex.Pers.) Fischer (syn. Phallus indusiatus). Biomedicines 7: 98. https://doi.org/10.3390/biomedicines7040098
    [29] Yuan S, Gopal JV, Ren S, et al. (2020) Anticancer fungal natural products: Mechanisms of action and biosynthesis. Eur J Med Chem 202: 112502. https://doi.org/10.1016/j.ejmech.2020.112502
    [30] Li YX, Himaya SWA, Dewapriya P, et al. (2013) Fumigaclavine C from a marine-derived fungus Aspergillus fumigatus induces apoptosis in MCF-7 breast cancer cells. Mar Drugs 11: 5063-5086. https://doi.org/10.3390/md11125063
    [31] Martirosyan A, Clendening JW, Goard CA, et al. (2010) Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: Potential therapeutic relevance. BMC Cancer 10: 103. https://doi.org/10.1186/1471-2407-10-103
    [32] Siddiqui RA, Harvey KA, Xu Z, et al. (2014) Characterization of lovastatin–docosahexaenoate anticancer properties against breast cancer cells. Bioorgan Med Chem 22: 1899-1908. https://doi.org/10.1016/j.bmc.2014.01.051
    [33] Hou H, Zhou R, Li A, et al. (2014) Citreoviridin inhibits cell proliferation and enhances apoptosis of human umbilical vein endothelial cells. Environ Toxicol Phar 37: 828-836. https://doi.org/10.1016/j.etap.2014.02.016
    [34] Turbyville TJ, Wijeratne EMK, Liu MX, et al. (2006) Search for Hsp90 inhibitors with potential anticancer activity: Isolation and SAR studies of radicicol and monocillin I from two plant-associated fungi of the Sonoran desert. J Nat Prod 69: 178-184. https://doi.org/10.1021/np058095b
    [35] Ishii S, Fujii M, Akita H (2009) First syntheses of (-)-tauranin and antibiotic (-)-BE-40644 based on lipase-catalyzed optical resolution of albicanol. Chem Pharm Bull 57: 1103-1106. https://doi.org/10.1248/cpb.57.1103
    [36] Jørgensen H (2009) Analysis of genes for the biosynthesis of polyene macrocyclic compounds in streptomycetes isolated from the Trondheimsfjord. NTNU Open .
    [37] Zhang J, Guo ZY, Shao CL, et al. (2022) Nigrosporins B, a potential anti-cervical cancer agent, induces apoptosis and protective autophagy in human cervical cancer Ca Ski cells mediated by PI3K/AKT/mTOR signaling pathway. Molecules 27: 2431. https://doi.org/10.3390/molecules27082431
    [38] Staker BL, Hjerrild K, Feese MD, et al. (2002) The mechanism of topoisomerase I poisoning by a camptothecinanalog. Proc Natl Acad Sci USA 99: 15387-15392. https://doi.org/10.1073/pnas.242259599
    [39] Liu YQ, Li WQ, Morris-Natschke SL, et al. (2015) Perspectives on biologically active camptothecin derivatives. Med Res Rev 35: 753-789. https://doi.org/10.1002/med.21342
    [40] Nguyen DQ, Nguyen NL, Nguyen VT, et al. (2023) Isolation and identification of vincristine and vinblastine producing endophytic fungi from Catharanthus roseus (L.) G. Don. Russ J Plant Physiol 70: 188. https://doi.org/10.1134/S1021443723601507
    [41] Mulac D, Lepski S, Ebert F, et al. (2013) Cytotoxicity and fluorescence visualization of ergot alkaloids in human cell lines. J Agric Food Chem 61: 462-471. https://doi.org/10.1021/jf304569q
    [42] Pal AK, Pal S (2023) Endophytic fungi as a medicinal repository of potential therapeutic compounds. J Mycopathol Res 61: 15-20. https://doi.org/10.57023/JMycR.61.1.2023.015
    [43] Kim YS, Kim SK, Park SJ (2017) Apoptotic effect of demethoxyfumitremorgin C from marine fungus Aspergillus fumigatus on PC3 human prostate cancer cells. Chem-Biol Interact 269: 18-24. https://doi.org/10.1016/j.cbi.2017.03.015
    [44] Islam F, Dehbia Z, Zehravi M, et al. (2023) Indole alkaloids from marine resources: Understandings from therapeutic point of view to treat cancers. Chem-Biol Interact 383: 110682. https://doi.org/10.1016/j.cbi.2023.110682
    [45] Paschall AV, Yang D, Lu C, et al. (2015) H3K9 trimethylation silences Fas expression to confer colon carcinoma immune escape and 5-fluorouracil chemoresistance. J Immunol 195: 1868-1882. https://doi.org/10.4049/jimmunol.1402243
    [46] Pierre HC, Amrine CSM, Doyle MG, et al. (2024) Verticillins: Fungal epipolythiodioxopiperazine alkaloids with chemotherapeutic potential. Nat Prod Rep 41: 1327-1345. https://doi.org/10.1039/D3NP00068K
    [47] Doi Y, Wakana D, Kitaoka S, et al. (2022) Secalonic acid and benzoic acid analogues exhibiting cytotoxicity against cancer cells isolated from Claviceps yanagawaensis. Adv Microbiol 12: 649-670. https://doi.org/10.4236/aim.2022.1212045
    [48] Meng Q, Li BX, Xiao X (2018) Toward developing chemical modulators of Hsp60 as potential therapeutics. Front Mol Biosci 5: 35.
    [49] Kassab MM (2023) Screening and production of fungal L-asparaginase enzymes as anticancer agents from high-contrast soil environments in Egypt. Egypt Acad J Biolog Sci G Microbiolog 15: 21-41.
    [50] Tiberghien F, Kurome T, Takesako K, et al. (2000) Aureobasidins: Structure−activity relationships for the inhibition of the human MDR1 P-glycoprotein ABC-transporter. J Med Chem 43: 2547-2556. https://doi.org/10.1021/jm990955w
    [51] López-Legarda X, Rostro-Alanis M, Parra-Saldivar R, et al. (2021) Submerged cultivation, characterization and in vitro antitumor activity of polysaccharides from Schizophyllumradiatum. Int J Biol Macromol 186: 919-932. https://doi.org/10.1016/j.ijbiomac.2021.07.084
    [52] Pirzadeh-Naeeni S, Mozdianfard MR, Shojaosadati SA, et al. (2020) A comparative study on schizophyllan and chitin nanoparticles for ellagic acid delivery in treating breast cancer. Int J Biol Macromol 144: 380-388. https://doi.org/10.1016/j.ijbiomac.2019.12.079
    [53] Gallego-Jara J, Lozano-Terol G, Sola-Martínez RA, et al. (2020) A comprehensive review about Taxol®: History and future challenges. Molecules 25: 5986. https://doi.org/10.3390/molecules25245986
    [54] Gond SK, Kharwar RN, White JF (2014) Will fungi be the new source of the blockbuster drug Taxol?. Fungal Biol Rev 28: 77-84. https://doi.org/10.1016/j.fbr.2014.10.001
    [55] Yang X, Wu P, Xue J, et al. (2023) Seco-pimarane diterpenoids and androstane steroids from an endophytic Nodulisporium fungus derived from Cyclosorusparasiticus. Phytochemistry 210: 113679. https://doi.org/10.1016/j.phytochem.2023.113679
    [56] Cadar E, Negreanu-Pirjol T, Pascale C, et al. (2023) Natural bio-compounds from Ganoderma lucidum and their beneficial biological actions for anticancer application: A review. Antioxidants 12: 1907. https://doi.org/10.3390/antiox12111907
    [57] Guo C, Dai H, Zhang M, et al. (2022) Molecular networking assisted discovery and combinatorial biosynthesis of new antimicrobial pleuromutilins. Eur J Med Chem 243: 114713. https://doi.org/10.1016/j.ejmech.2022.114713
    [58] Evidente A (2024) The incredible story of ophiobolin A and sphaeropsidin A: Two fungal terpenes from wilt-inducing phytotoxins to promising anticancer compounds. Nat Prod Rep 41: 434-468. https://doi.org/10.1039/D3NP00035D
    [59] Zheng Q, Sun J, Li W, et al. (2020) Cordycepin induces apoptosis in human tongue cancer cells in vitro and has antitumor effects in vivo. Arch Oral Biol 118: 104846. https://doi.org/10.1016/j.archoralbio.2020.104846
    [60] Xiang M, Kim H, Ho VT, et al. (2016) Gene expression–based discovery of atovaquone as a STAT3 inhibitor and anticancer agent. Blood 128: 1845-1853. https://doi.org/10.1182/blood-2015-07-660506
    [61] Cheng L, Yan B, Chen K, et al. (2018) Resveratrol-induced downregulation of NAF-1 enhances the sensitivity of pancreatic cancer cells to gemcitabine via the ROS/Nrf2 signaling pathways. Oxid Med Cell Longev 2018: 9482018. https://doi.org/10.1155/2018/9482018
    [62] Gangwar C, Yaseen B, Nayak R, et al. (2022) Silver nanoparticles fabricated by tannic acid for their antimicrobial and anticancerous activity. Inorg Chem Commun 141: 109532. https://doi.org/10.1016/j.inoche.2022.109532
    [63] Naidu SD, Dinkova-Kostova AT (2017) Regulation of the mammalian heat shock factor 1. FEBS J 284: 1606-1627. https://doi.org/10.1111/febs.13999
    [64] Carroll G (1988) Fungal endophytes in stems and leaves: From latent pathogen to mutualistic symbiont. Ecology 69: 2-9. https://doi.org/10.2307/1943154
    [65] Zhao J, Shan T, Mou Y, et al. (2011) Plant-derived bioactive compounds produced by endophytic fungi. Mini-Rev Med Chem 11: 159-168. https://doi.org/10.2174/138955711794519492
    [66] Monacelli B, Valletta A, Rascio N, et al. (2005) Laticifers in Camptotheca acuminate Decne: Distribution and structure. Protoplasma 226: 155-161. https://doi.org/10.1007/s00709-005-0118-2
    [67] Ran X, Zhang G, Li S, et al. (2017) Characterization and antitumor activity of camptothecin from endophytic fungus Fusarium solani isolated from Camptotheca acuminata. Afr Health Sci 17: 566-574. https://doi.org/10.4314/ahs.v17i2.34
    [68] Kumar A (2016) Vincristine and vinblastine: A review. IJMPS : 23-30.
    [69] Goodbody A, Endo T, Vukovic J, et al. (1988) The coupling of catharanthine and vindoline to form 3′,4′-anhydrovinblastine by haemoproteins and haemin. Planta Med 54: 210-214.
    [70] Kutchan TM (1995) Alkaloid biosynthesis—the basis for metabolic engineering of medicinal plants. Plant Cell 7: 1059-1070. https://doi.org/10.1105/tpc.7.7.1059
    [71] Kalidass A, Mohan VR, Daniel C (2009) Effect of auxin and cytokinin on vincristine production by callus cultures of Catharanthus roseus L. (Apocynaceae). Trop SubtropicalAgroecosys 12: 283-288.
    [72] Ramezani A, Haddad R, Sedaghati B, et al. (2018) Effects of fungal extracts on vinblastine and vincristine production and their biosynthesis pathway genes in Catharanthus roseus. S Afr J Bot 119: 163-171. https://doi.org/10.1016/j.sajb.2018.08.015
    [73] Mrusek M, Seo EJ, Greten HJ, et al. (2015) Identification of cellular and molecular factors determining the response of cancer cells to six ergot alkaloids. Invest New Drugs 33: 32-44. https://doi.org/10.1007/s10637-014-0168-4
    [74] Tudzynski P, Correia T, Keller U (2001) Biotechnology and genetics of ergot alkaloids. Appl Microbiol Biotechnol 57: 593-605. https://doi.org/10.1007/s002530100801
    [75] Coyle CM, Panaccione DG (2005) An ergot alkaloid biosynthesis gene and clustered hypothetical genes from Aspergillus fumigatus. Appl Environ Microbiol 71: 3112-3118. https://doi.org/10.1128/AEM.71.6.3112-3118.2005
    [76] Song J, Zhang B, Li M, et al. (2023) The current scenario of naturally occurring indole alkaloids with anticancer potential. Fitoterapia 165: 105430. https://doi.org/10.1016/j.fitote.2023.105430
    [77] Peng F, Hou SY, Zhang TY, et al. (2019) Cytotoxic and antimicrobial indole alkaloids from an endophytic fungus Chaetomium sp. SYP-F7950 of Panax notoginseng. RSC Adv 9: 28754-28763. https://doi.org/10.1039/C9RA04747F
    [78] Ding Y, de Wet JR, Cavalcoli J, et al. (2010) Genome-based characterization of two prenylation steps in the assembly of the stephacidin and notoamide anticancer agents in a marine-derived Aspergillus sp. J Am Chem Soc 132: 12733-12740. https://doi.org/10.1021/ja1049302
    [79] Salvi A, Amrine CSM, Austin JR, et al. (2020) Verticillin A causes apoptosis and reduces tumor burden in high-grade serous ovarian cancer by inducing DNA damage. Mol Cancer Ther 19: 89-100. https://doi.org/10.1158/1535-7163.MCT-19-0205
    [80] Strobel GA, Torczynski R, Bollon A (1997) Acremonium sp.—Aleucinostatin A producing endophyte of European yew (Taxus baccata). Plant Sci 128: 97-108. https://doi.org/10.1016/S0168-9452(97)00131-3
    [81] Moharib SA (2018) Anticancer activity of L-asparaginase produced from Vigna unguiculata. World Sci Res 5: 1-12. https://doi.org/10.20448/journal.510.2018.51.1.12
    [82] Hassan SWM, Farag AM, Beltagy EA (2018) Purification, characterization, and anticancer activity of L-asparaginase produced by marine Aspergillus terreus. J Pure Appl Microbiol 12: 1845-1854. https://doi.org/10.22207/JPAM.12.4.19
    [83] Wang LG, Liu XM, Kreis W, et al. (1999) The effect of antimicrotubule agents on signal transduction pathways of apoptosis: A review. Cancer Chemother Pharmacol 44: 355-361. https://doi.org/10.1007/s002800050989
    [84] Robinson DR, Wu YM, Lonigro RJ, et al. (2017) Integrative clinical genomics of metastatic cancer. Nature 548: 297-303. https://doi.org/10.1038/nature23306
    [85] Nakamura K, Shinozuka K, Yoshikawa N (2015) Anticancer and antimetastatic effects of cordycepin, an active component of Cordyceps sinensis. J Pharmacol Sci 127: 53-56. https://doi.org/10.1016/j.jphs.2014.09.001
    [86] Tao X, Ning Y, Zhao X, et al. (2016) The effects of cordycepin on the cell proliferation, migration, and apoptosis in human lung cancer cell lines A549 and NCI-H460. J Pharm Pharmacol 68: 901-911. https://doi.org/10.1111/jphp.12544
    [87] Wong JH, Ng TB, Chan HHL, et al. (2020) Mushroom extracts and compounds with suppressive action on breast cancer: evidence from studies using cultured cancer cells, tumor-bearing animals, and clinical trials. Appl Microbiol Biotechnol 104: 4675-4703. https://doi.org/10.1007/s00253-020-10476-4
    [88] Gill BS, Kumar S, Navgeet (2018) Ganoderic acid A targeting β-catenin in Wntsignaling pathway: In silico and in vitro study. Interdiscip Sci Comput Life Sci 10: 233-243. https://doi.org/10.1007/s12539-016-0182-7
    [89] Gill BS, Navgeet, Mehra R, et al. (2018) Ganoderic acid, lanostanoid triterpene: A key player in apoptosis. Invest New Drugs 36: 136-143. https://doi.org/10.1007/s10637-017-0526-0
    [90] Jiang J, Grieb B, Thyagarajan A, Sliva D (2008) Ganoderic acids suppress growth and invasive behavior of breast cancer cells by modulating AP-1 and NF-κB signaling. Int J Mol Med 21: 577-584.
    [91] Yamane M, Minami A, Liu C, et al. (2017) Biosynthetic machinery of diterpene pleuromutilin isolated from basidiomycete fungi. Chem Bio Chem 18: 2317-2322. https://doi.org/10.1002/cbic.201700434
    [92] Uzma F, Mohan CD, Hashem A, et al. (2018) Endophytic fungi—alternative sources of cytotoxic compounds: A review. Front Pharmacol 9: 309.
    [93] Nadeem M, Ram M, Alam P, et al. (2012) Fusarium solani, P1, a new endophyticpodophyllotoxin-producing fungus from roots of Podophyllum hexandrum. Afr J Microbiol Res 6: 2493-2499.
    [94] Shi J, Zeng Q, Liu Y, et al. (2012) Alternaria sp. MG1, a resveratrol-producing fungus: isolation, identification, and optimal cultivation conditions for resveratrol production. Appl Microbiol Biotechnol 95: 369-379. https://doi.org/10.1007/s00253-012-4045-9
    [95] Guruceaga X, Perez-Cuesta U, de Cerio AAD, et al. (2019) Fumagillin, a mycotoxin of Aspergillus fumigatus: biosynthesis, biological activities, detection, and applications. Toxins 12: 7. https://doi.org/10.3390/toxins12010007
    [96] National Center for Biotechnology Information (NCBI)PubChem Compound Summary for CID 6917655, Fumagillin (2025). Available from: https://pubchem.ncbi.nlm.nih.gov/compound/6917655
    [97] Khandelwal KA, Han S, Won YW, et al. (2021) Complex interactions of lovastatin with 10 chemotherapeutic drugs: A rigorous evaluation of synergism and antagonism. BMC Cancer 21: 356. https://doi.org/10.1186/s12885-021-07963-w
    [98] Ma HT, Poon RYC (2017) Synchronization of HeLa cells. Cell cycle synchronization. New York: Humana Press 189-201. https://doi.org/10.1007/978-1-4939-6603-5_12
    [99] Ikuina Y, Amishiro N, Miyata M, et al. (2003) Synthesis and antitumor activity of novel O-carbamoylmethyloxime derivatives of radicicol. J Med Chem 46: 2534-2541. https://doi.org/10.1021/jm030110r
    [100] Soga S, Shiotsu Y, Akinaga S, et al. (2003) Development of radicicol analogues. Curr Cancer Drug Tar 3: 359-369. https://doi.org/10.2174/1568009033481859
    [101] Newman DJ, Cragg GM (2007) Natural products as sources of new drugs over the last 25 years. J Nat Prod 70: 461-477. https://doi.org/10.1021/np068054v
    [102] Kusari S, Hertweck C, Spiteller M (2012) Chemical ecology of endophytic fungi: Origins of secondary metabolites. Chem Biol 19: 792-798. https://doi.org/10.1016/j.chembiol.2012.06.004
    [103] Kusari S, Zühlke S, Spiteller M (2009) An endophytic fungus from Camptotheca acuminata that produces camptothecin and analogues. J Nat Prod 72: 2-7. https://doi.org/10.1021/np800455b
    [104] Demain AL, Vaishnav P (2011) Natural products for cancer chemotherapy. MicrobBiotechnol 4: 687-699. https://doi.org/10.1111/j.1751-7915.2010.00221.x
    [105] Xie S, Zhou J (2017) Harnessing plant biodiversity for the discovery of novel anticancer drugs targeting microtubules. Front Plant Sci 8: 720. https://doi.org/10.3389/fpls.2017.00720
    [106] Lei M, Ribeiro H, Kolodin G, et al. (2013) Establishing a high-throughput and automated cancer cell proliferation panel for oncology lead optimization. SLAS Discov 18: 1043-1053. https://doi.org/10.1177/1087057113491825
    [107] Aly AH, Edrada-Ebel R, Indriani ID, et al. (2008) Cytotoxic metabolites from the fungal endophyte Alternaria sp. and their subsequent detection in its host plant Polygonum senegalense. J Nat Prod 71: 972-980. https://doi.org/10.1021/np070447m
    [108] Salvador-Reyes LA, Luesch H (2015) Biological targets and mechanisms of action of natural products from marine cyanobacteria. Nat Prod Rep 32: 478-503. https://doi.org/10.1039/C4NP00104D
    [109] Stierle AA, Stierle DB (2015) Bioactive secondary metabolites produced by the fungal endophytes of conifers. Nat Prod Commun 10: 1671-1682.
    [110] Balunas MJ, Kinghorn AD (2005) Drug discovery from medicinal plants. Life Sci 78: 431-441. https://doi.org/10.1016/j.lfs.2005.09.012
    [111] Saltz L, Shimada Y, Khayat D (1996) CPT-11 (irinotecan) and 5-fluorouracil: A promising combination for therapy of colorectal cancer. Eur J Cancer 32: S24-31. https://doi.org/10.1016/0959-8049(96)00294-8
    [112] Mei C, Lei L, Tan LM, et al. (2020) The role of single strand break repair pathways in cellular responses to camptothecin induced DNA damage. Biomed Pharmacother 125: 109875. https://doi.org/10.1016/j.biopha.2020.109875
    [113] Li M, Wang L, Wei Y, et al. (2022) Anti-colorectal cancer effects of a novel camptothecin derivative PCC0208037 in vitro and in vivo. Pharmaceuticals 16: 53. https://doi.org/10.3390/ph16010053
    [114] Kaur P, Kumar V, Singh R, et al. (2020) Biotechnological strategies for production of camptothecin from fungal and bacterial endophytes. South Afr J Bot 134: 135-145. https://doi.org/10.1016/j.sajb.2020.07.001
    [115] Banadka A, Narasimha SW, Dandin VS, et al. (2024) Biotechnological approaches for the production of camptothecin. Appl Microbiol Biotechnol 108: 382. https://doi.org/10.1007/s00253-024-13187-2
    [116] Bates D, Eastman A (2017) Microtubuledestabilizing agents: Far more than just antimitotic anticancer drugs. Br J Clin Pharmacol 83: 255-268. https://doi.org/10.1111/bcp.13126
    [117] Javeed A, Ashraf M, Riaz A, et al. (2009) Paclitaxel and immune system. Eur J Pharm Sci 38: 283-290. https://doi.org/10.1016/j.ejps.2009.08.009
    [118] Lim PT, Goh BH, Lee WL (2022) Taxol: Mechanisms of action against cancer, an update with current research. Paclitaxel.Elsevier 47-71. https://doi.org/10.1016/B978-0-323-90951-8.00007-2
    [119] Kusari S, Singh S, Jayabaskaran C (2014) Rethinking production of Taxol® (paclitaxel) using endophyte biotechnology. Trends Biotechnol 32: 304-311. https://doi.org/10.1016/j.tibtech.2014.03.011
    [120] Zerbe P (2024) Plants against cancer: Towards green Taxol production through pathway discovery and metabolic engineering. aBIOTECH 5: 394-402. https://doi.org/10.1007/s42994-024-00170-8
    [121] Wong YY, Moon A, Duffin R, et al. (2010) Cordycepin inhibits protein synthesis and cell adhesion through effects on signal transduction. J Biol Chem 285: 2610-2621. https://doi.org/10.1074/jbc.M109.071159
    [122] Jin Y, Meng X, Qiu Z, et al. (2018) Anti-tumor and anti-metastatic roles of cordycepin, one bioactive compound of Cordyceps militaris. Saudi J Biol Sci 25: 991-995. https://doi.org/10.1016/j.sjbs.2018.05.016
    [123] Hwang IH, Oh SY, Jang HJ, et al. (2017) Cordycepin promotes apoptosis in renal carcinoma cells by activating the MKK7-JNK signaling pathway through inhibition of c-FLIPL expression. PLoS One 12: e0186489. https://doi.org/10.1371/journal.pone.0186489
    [124] Hsu PY, Lin YH, Yeh EL, et al. (2017) Cordycepin and a preparation from Cordyceps militaris inhibit malignant transformation and proliferation by decreasing EGFR and IL-17RA signaling in a murine oral cancer model. Oncotarget 8: 93712-93728. https://doi.org/10.18632/oncotarget.21477
    [125] Joo JC, Hwang JH, Jo E, et al. (2017) Cordycepin induces apoptosis by caveolin-1-mediated JNK regulation of Foxo3a in human lung adenocarcinoma. Oncotarget 8: 12211-12224. https://doi.org/10.18632/oncotarget.14661
    [126] Wu X, Wu T, Huang A, et al. (2021) New insights into the biosynthesis of typical bioactive components in the traditional Chinese medicinal fungus Cordyceps militaris. Front Bioeng Biotechnol 9: 801721. https://doi.org/10.3389/fbioe.2021.801721
    [127] Yoo CH, Sadat MA, Kim W, et al. (2022) Comprehensive transcriptomic analysis of Cordyceps militaris cultivated on germinated soybeans. Mycobiology 50: 1-11. https://doi.org/10.1080/12298093.2022.2035906
    [128] Frottin F, Bienvenut WV, Bignon J, et al. (2016) MetAP1 and MetAP2 drive cell selectivity for a potent anti-cancer agent in synergy, by controlling glutathione redox state. Oncotarget 7: 63306-63323. https://doi.org/10.18632/oncotarget.11216
    [129] Lin HC, Chooi YH, Dhingra S, et al. (2013) The fumagillin biosynthetic gene cluster in Aspergillus fumigatus encodes a cryptic terpene cyclase involved in the formation of β-trans-Bergamotene. J Am Chem Soc 135: 4616-4619. https://doi.org/10.1021/ja312503y
    [130] Zhang Y, Yeh JR, Mara A, et al. (2006) A chemical and genetic approach to the mode of action of fumagillin. Chem Biol 13: 1001-1009. https://doi.org/10.1016/j.chembiol.2006.07.010
    [131] Yang T, Yao H, He G, et al. (2016) Effects of lovastatin on MDA-MB-231 breast cancer cells: An antibody microarray analysis. J Cancer 7: 192-199. https://doi.org/10.7150/jca.13414
    [132] Maksimova E, Yie TA, Rom WN (2008) In vitro mechanisms of lovastatin on lung cancer cell lines as a potential chemo preventive eagent. Lung 186: 45-54. https://doi.org/10.1007/s00408-007-9053-7
    [133] Ames BD, Nguyen C, Bruegger J, et al. (2012) Crystal structure and biochemical studies of the trans-acting polyketide enoyl reductase LovC from lovastatin biosynthesis. Proc Natl Acad Sci USA 109: 11144-11149. https://doi.org/10.1073/pnas.1113029109
    [134] Zhang Y, Chen Z, Wen Q, et al. (2020) An overview on the biosynthesis and metabolic regulation of monacolin K/Lovastatin. Food Funct 11: 5738-5748. https://doi.org/10.1039/D0FO00691B
    [135] Sun X, Xu Q, Zeng L, et al. (2020) Resveratrol suppresses the growth and metastatic potential of cervical cancer by inhibiting STAT3Tyr705 phosphorylation. Cancer Medicine 9: 8685-8700. https://doi.org/10.1002/cam4.3510
    [136] Brockmueller A, Girisa S, Kunnumakkara AB, et al. (2023) Resveratrol modulates chemosensitization to 5-FU via β1-Integrin/HIF-1α axis in CRC tumor microenvironment. Int J Mol Sci 24: 4988. https://doi.org/10.3390/ijms24054988
    [137] Li J, Fan Y, Zhang Y, et al. (2022) Resveratrol induces autophagy and apoptosis in non-small-cell lung cancer cells by activating the NGFR-AMPK-mTOR pathway. Nutrients 14: 2413. https://doi.org/10.3390/nu14122413
    [138] Meng T, Xiao D, Muhammed A, et al. (2021) Anti-inflammatory action and mechanisms of resveratrol. Molecules 26: 229. https://doi.org/10.3390/molecules26010229
    [139] Abo-Kadoum MA, Abouelela ME, Al Mousa AA, et al. (2022) Resveratrol biosynthesis, optimization, induction, biotransformation and biodegradation in mycoendophytes. Front Microbiol 13: 010332. https://doi.org/10.3389/fmicb.2022.1010332
    [140] Schwab W, Lange BM, Wüst M (2018) Biotechnology of natural products.Springer. https://doi.org/10.1007/978-3-319-67903-7
    [141] Groth-Pedersen L, Ostenfeld MS, Høyer-Hansen M, et al. (2007) Vincristine induces dramatic lysosomal changes and sensitizes cancer cells to lysosome-destabilizing siramesine. Cancer Res 67: 2217-2225. https://doi.org/10.1158/0008-5472.CAN-06-3520
    [142] Bates D, Eastman A (2017) Microtubule destabilizing agents: Far more than just antimitotic anticancer drugs. Brit J Clini Pharmaco 8: 255-268. https://doi.org/10.1111/bcp.13126
    [143] Pandey SS, Singh S, Babu CSV, et al. (2016) Fungal endophytes of Catharanthus roseusenhance vindoline content by modulating structural and regulatory genes related to terpenoid indole alkaloid biosynthesis. Sci Rep 6: 26583. https://doi.org/10.1038/srep26583
    [144] Ye L (2015) Synthetic strategies in molecular imprinting. Molecularly imprinted polymers in biotechnology. Cham: Springer 1-24. https://doi.org/10.1007/10_2015_313
    [145] Gao D, Liu T, Gao J, et al. (2022) De Novobiosynthesis of vindoline and catharanthine in Saccharomyces cerevisiae. Bio Design Res 2022: 0022. https://doi.org/10.34133/bdr.0002
    [146] Jeitler M, Michalsen A, Frings D, et al. (2020) Significance of medicinal mushrooms in integrative oncology: A narrative review. Front Pharmacol 11: 580656. https://doi.org/10.3389/fphar.2020.580656
    [147] Grant SJ, Hunter J, Seely, D, et al. (2019) Integrative oncology: International perspectives. Integr Cancer Ther 18: 1-11. https://doi.org/10.1177/1534735418823266
    [148] Plácido AI, Roque F, Morgado M (2022) The promising role of mushrooms as a therapeutic adjuvant of conventional cancer therapies. Biologics 2: 58-68. https://doi.org/10.3390/biologics2010005
    [149] Tsai MY, Hung YC, Chen YH, et al. (2016) A preliminary randomised controlled study of short-term Antrodiacinnamomea treatment combined with chemotherapy for patients with advanced cancer. BMC Complement Altern Med 16: 322. https://doi.org/10.1186/s12906-016-1312-9
    [150] Tsao SM, Hsu HY (2016) Fucose-containing fraction of Ling-Zhi enhances lipid raft-dependent ubiquitination of TGFβ receptor degradation and attenuates breast cancer tumorigenesis. Sci Rep 6: 36563. https://doi.org/10.1038/srep36563
    [151] Roldan-Deamicis A, Alonso E, Brie B, et al. (2016) Maitake Pro4X has anti-cancer activity and prevents oncogenesis in BALB/c mice. Cancer Med 5: 2427-2441. https://doi.org/10.1002/cam4.744
    [152] Gou Y, Zheng X, Li W, et al. (2022) Polysaccharides produced by the mushroom Trametes robiniophila Murrboost the sensitivity of hepatoma cells to oxaliplatin via the miR-224-5p/ABCB1/P-gpaxis. Integr Cancer Ther 21. https://doi.org/10.1177/15347354221090221
    [153] Xu WW, Li B, Lai ETC, et al. (2014) Water extract from Pleurotus pulmonarius with antioxidant activity exerts in vivochemoprophylaxis and chemosensitization for liver cancer. Nutr Cancer 66: 989-998. https://doi.org/10.1080/01635581.2014.936950
    [154] Cen K, Chen M, He M, et al. (2022) Sporoderm-broken spores of Ganoderma lucidum sensitize ovarian cancer to cisplatin by ROS/ERK signaling and attenuate chemotherapy-related toxicity. Front Pharmacol 13: 826716. https://doi.org/10.3389/fphar.2022.826716
    [155] De Luca F, Roda E, Ratto D, et al. (2023) Fighting secondary triple-negative breast cancer in cerebellum: A powerful aid from a medicinal mushrooms blend. Biomed Pharmacother 159: 114262. https://doi.org/10.1016/j.biopha.2023.114262
    [156] Lyons MJ, Ehrhardt C, Walsh JJ (2023) Orellanine: From fungal origin to a potential future cancer treatment. J Natural Prod 86: 1620-1631. https://doi.org/10.1021/acs.jnatprod.2c01068
    [157] Ling T, Arroyo-Cruz LV, Smither WR, et al. (2024) Early preclinical studies of ergosterol peroxide and biological evaluation of its derivatives. ACS Omega 9: 37117-37127. https://doi.org/10.1021/acsomega.4c04350
    [158] Panda SK, Sahoo G, Swain SS, et al. (2022) Anticancer activities of mushrooms: A neglected source for drug discovery. Pharmaceuticals 15: 176. https://doi.org/10.3390/ph15020176
    [159] Zhao H, Zhang Q, Zhao L, et al. (2012) Spore powder of Ganoderma lucidum improves cancer-related fatigue in breast cancer patients undergoing endocrine therapy: A pilot clinical trial. Evid-Based Compl Alt Med 2012: 809614. https://doi.org/10.1155/2012/809614
  • molsci-12-01-005-s001.pdf
  • This article has been cited by:

    1. Cheng-Cheng Zhu, Jiang Zhu, Dynamic analysis of a delayed COVID-19 epidemic with home quarantine in temporal-spatial heterogeneous via global exponential attractor method, 2021, 143, 09600779, 110546, 10.1016/j.chaos.2020.110546
    2. Jinliang Wang, Ran Zhang, Toshikazu Kuniya, A reaction–diffusion Susceptible–Vaccinated–Infected–Recovered model in a spatially heterogeneous environment with Dirichlet boundary condition, 2021, 190, 03784754, 848, 10.1016/j.matcom.2021.06.020
    3. Cheng-Cheng Zhu, Jiang Zhu, The effect of self-limiting on the prevention and control of the diffuse COVID-19 epidemic with delayed and temporal-spatial heterogeneous, 2021, 21, 1471-2334, 10.1186/s12879-021-06670-y
    4. Mohamed Mehdaoui, Abdesslem Lamrani Alaoui, Mouhcine Tilioua, Analysis of an optimal control problem for a spatio‐temporal SIR model with nonlinear density dependent diffusion terms, 2023, 0143-2087, 10.1002/oca.2976
    5. Cheng-Cheng Zhu, Jiang Zhu, Spread trend of COVID-19 epidemic outbreak in China: using exponential attractor method in a spatial heterogeneous SEIQR model, 2020, 17, 1551-0018, 3062, 10.3934/mbe.2020174
    6. Séverin Foko, Calvin Tadmon, Analysis of a delayed spatiotemporal model of HBV infection with logistic growth, 2024, 103, 0003-6811, 2283, 10.1080/00036811.2023.2291813
    7. Yantao Luo, Yunqiang Yuan, Zhidong Teng, ANALYSIS OF A DEGENERATED DIFFUSION SVEQIRV EPIDEMIC MODEL WITH GENERAL INCIDENCE IN A SPACE HETEROGENEOUS ENVIRONMENT, 2024, 14, 2156-907X, 2704, 10.11948/20230346
    8. Vasyl’ Davydovych, Vasyl’ Dutka, Roman Cherniha, Reaction–Diffusion Equations in Mathematical Models Arising in Epidemiology, 2023, 15, 2073-8994, 2025, 10.3390/sym15112025
    9. Chang Zhai, Ping Chen, Zhuo Jin, Tak Kuen Siu, Epidemic modelling and actuarial applications for pandemic insurance: a case study of Victoria, Australia, 2024, 18, 1748-4995, 242, 10.1017/S1748499523000246
    10. Cheng-Cheng Zhu, Jiang Zhu, Jie Shao, Epidemiological Investigation: Important Measures for the Prevention and Control of COVID-19 Epidemic in China, 2023, 11, 2227-7390, 3027, 10.3390/math11133027
    11. Cheng-Cheng Zhu, Jiang Zhu, The existence conditions for global exponential attractor of non-autonomous evolution equations and applications, 2023, 173, 09600779, 113711, 10.1016/j.chaos.2023.113711
    12. Pengfei Liu, Yantao Luo, Zhidong Teng, Role of media coverage in a SVEIR-I epidemic model with nonlinear incidence and spatial heterogeneous environment, 2023, 20, 1551-0018, 15641, 10.3934/mbe.2023698
    13. Linhe Zhu, Yue Li, Le He, Shuling Shen, Pattern formation of network epidemic model and its application in oral medicine, 2025, 264, 01692607, 108688, 10.1016/j.cmpb.2025.108688
  • Reader Comments
  • © 2025 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(253) PDF downloads(16) Cited by(0)

Figures and Tables

Figures(8)

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog